

SPARC/Sec/SE/2021-22/32

8<sup>th</sup> July 2021

National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051. **BSE Limited,** Market Operations Dept. P. J. Towers, Dalal Street, Mumbai - 400 001.

Ref: Scrip Code: NSE: SPARC; BSE: 532872

Dear Sir/ Madam,

## <u>Sub:</u> Intimation of Outcome of the meeting of the Securities Allotment Committee held today i.e. on July 08, 2021, in terms of Regulation 30 read with Schedule III of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Pursuant to the approval of the Board of Directors at its meeting held on May 12, 2021 and approval of the members of the Company at their Extra-Ordinary General Meeting held on June 08, 2021 and pursuant to In-principle approvals granted by BSE Limited and National Stock Exchange of India Limited vide their respective letters dated June 24, 2021 and upon receipt of an amount aggregating to Rs. 278,00,96,649 (Rupees Two Hundred Seventy Eight Crores Ninety Six Thousand Six Hundred and Forty Nine only) at the rate of Rs. 44.50 per warrant (being 25% of the issue price per warrant) as warrant subscription price and application forms from the 31 proposed allottees, the Securities Allotment Committee of the Board of Directors of the Company, has considered and approved the Allotment of 6,24,74,082 (Six Crore Twenty Four Lakhs Seventy Four Thousand and Eighty Two) warrants on preferential basis at an issue price [including the warrant subscription price (Rs. 44.50 per warrant) and the warrant exercise price (Rs. 133.50 per warrant)] of Rs. 178/each (Rupees One Hundred and Seventy Eight only) aggregating to Rs. 1112,03,86,596 (Rupees One Thousand One Hundred Twelve Crore Three Lakhs Eighty Six Thousand Five Hundred and Ninety Six only), to Mr. Dilip Shantilal Shanghvi, Promoter of the Company and to certain other non-promoter persons/ entities ('Allottees') (as per the list enclosed marked as Annexure I).

Each of the Warrant, so allotted, is convertible into or exchangeable for one fully paidup equity share of face value of Re. 1/- (Rupee One only) of the Company in accordance with the provisions of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, on payment of the balance

Sun Pharma Advanced Research Company Ltd.

17/B, Mahal Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India. Tel.: (91-22) 6645 5645 | Fax.: (91-22) 6645 5685 | CIN: L73100GJ2006PLC047837 | Website: www.sparc.life



consideration of Rs. 133.50/- per warrant (being 75% of the issue price per warrant) from the Allottees at the time of allotment of equity shares pursuant to exercise of conversion option against each such warrant.

As against the approval (from the Board of Directors and members of the Company) for issue of 6,74,70,203 warrants, the Committee has allotted only 6,24,74,082 warrants, due to, non-receipt of warrant subscription money by the proposed allottees and / or non-receipt of In-principle approval from the Stock Exchanges on some warrants.

The meeting of the Committee commenced at 09:00 a.m. and concluded at 09:15 a.m.

Thanking you,

Yours faithfully,

For Sun Pharma Advanced Research Company Ltd.

Chetan Rajpara Chief Financial Officer

Encl – as above

Sun Pharma Advanced Research Company Ltd. 17/B, Mahal Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India. Tel.: (91-22) 6645 5645 | Fax.: (91-22) 6645 5685 | CIN: L73100GJ2006PLC047837 | Website: www.sparc.life



## Annexure 1

## List of Allottees

Sr.	Name of the Allottee	No. of Warrants Allotted
No. 1	Dilip Shantilal Shanghvi	3,37,07,865
2	Rekha Jhunjhunwala	62,92,134
3	Enam Securities Private Limited	33,70,786
4	ITI Holdings and Investment Private Limited	28,08,988
5	Minosha India Limited	16,85,393
6	University of Notre Dame DU Lac	15,38,033
7	Abakkus Growth Fund – 1	14,04,494
8	Cohesion MK Best Ideas Sub-Trust	14,04,494
9	Winro Commercial (India) Limited	12,92,134
10	Amal N. Parikh	11,23,595
11	Singularity Holdings Limited	9,55,056
12	Trishakti Power Holdings Private Limited	7,02,247
13	Arun Nahar	5,61,797
14	Fortune Financial & Equities Services Private Limited	5,61,797
15	Jash Choraria	5,61,797
16	Ketan Chhotalal Sheth	5,61,797
17	Pivotal Enterprises Private Limited	5,61,797
18	Dovetail India Fund Class 11 Shares	5,33,707
19	The Ram Fund, L.P.	4,74,269
20	GP Emerging Markets Strategies, L.P.	4,41,123
21	Sanjana Cryogenic Storages Limited	3,37,078
22	Geecee Ventures Limited	2,80,898
23	Shruti Gagan Chaturvedi	2,80,898
24	Amit Goela	2,01,123
25	Massachusetts Institute of Technology	1,79,775
26	Pragma Fund SPC- Equities Segregated Portfolio	1,71,235
27	Avinash Sudhir Sule	1,66,292
28	Nipa Sheth	1,00,561
29	Utpal Sheth	1,00,561
30	Ashish Maheshwari	84,269
31	Dovetail India Fund - Class 6 Shares	28,089
	Total	6,24,74,082

For Sun Pharma Advanced Research Company Ltd.

**Chetan Rajpara** Chief Financial Officer

Sun Pharma Advanced Research Company Ltd.

17/B, Mahal Industrial Estate, Off Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India. Tel.: (91-22) 6645 5645 | Fax.: (91-22) 6645 5685 | CIN: L73100GJ2006PLC047837 | Website: www.sparc.life